DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ditropan (Oxybutynin) - Cerebral Atrophy - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Cerebral Atrophy (4)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Ditropan (Oxybutynin) where reactions include cerebral atrophy. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Ditropan side effects in 72 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-02

Patient: 72 year old female

Reactions: Confusional State, Iatrogenic Injury, Cerebral Atrophy, Cognitive Disorder, Parkinsonism, Leukoencephalopathy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Xenazine
    Start date: 2007-10-01
    End date: 2010-03-01

Ditropan
    Start date: 2007-11-01
    End date: 2011-10-01

Azilect
    Indication: Parkinsonism
    Start date: 2011-07-01
    End date: 2011-10-01

Cymbalta
    Start date: 2009-11-01
    End date: 2011-10-01

Exelon
    Start date: 2011-09-01
    End date: 2011-10-01



Possible Ditropan side effects in 72 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-31

Patient: 72 year old female

Reactions: Cerebral Disorder, Iatrogenic Injury, Cerebral Atrophy, Cognitive Disorder, Leukoencephalopathy, Parkinsonism

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ditropan
    Start date: 2007-11-01
    End date: 2011-10-01

Azilect
    Indication: Parkinsonism
    Start date: 2011-07-01
    End date: 2011-10-01

Xenazine
    Start date: 2007-10-01
    End date: 2010-03-01

Cymbalta
    Start date: 2009-11-01
    End date: 2011-10-01

Exelon
    Start date: 2011-09-01
    End date: 2011-10-01



Possible Ditropan side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-03-05

Patient: female

Reactions: Confusional State, Iatrogenic Injury, Cerebral Atrophy, Parkinsonism, Cognitive Disorder, Leukoencephalopathy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Xenazine
    Dosage: (25 mg bid oral)
    Administration route: Oral
    Indication: Dyskinesia
    Start date: 2007-10-01
    End date: 2010-03-01

Exelon
    Dosage: (9.5 mg qd transdermal)
    Indication: Cognitive Disorder
    Start date: 2011-09-01
    End date: 2011-10-01

Ditropan
    Dosage: (5 mg tid oral)
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2007-11-01
    End date: 2011-10-01

Azilect
    Dosage: (30 mg qd oral)
    Administration route: Oral
    Indication: Parkinsonism
    Start date: 2011-07-01
    End date: 2011-10-01

Cymbalta
    Dosage: (120 mg, 60mg in the morning and 60mg in the evening oral)
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2009-11-01
    End date: 2011-10-01



Possible Ditropan side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2011-11-29

Patient: female

Reactions: Cerebral Disorder, Iatrogenic Injury, Cerebral Atrophy, Parkinsonism, Leukoencephalopathy, Cognitive Disorder

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cymbalta
    Dosage: (120 mg, 60mg in the morning and 60mg in the evening oral)
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2009-11-01
    End date: 2011-10-01

Xenazine
    Dosage: (25 mg bid oral)
    Administration route: Oral
    Indication: Dyskinesia
    Start date: 2007-10-01
    End date: 2010-03-01

Azilect
    Dosage: (30 mg qd oral)
    Administration route: Oral
    Indication: Parkinsonism
    Start date: 2011-07-01
    End date: 2011-10-01

Ditropan
    Dosage: (5 mg tid oral)
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2007-11-01
    End date: 2011-10-01

Exelon
    Dosage: (9.5 mg qd transdermal)
    Indication: Cognitive Disorder
    Start date: 2011-09-01
    End date: 2011-10-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017